Kmart Pharmacy serves up low-cost EpiPen generic

Print Friendly, PDF & Email
Kmart pharmacist with patient_Kmart Pharmacy

HOFFMAN ESTATES, Ill. — Kmart Pharmacy is tackling the cost issue with epinephrine auto-injectors for anaphylaxis by knocking down the price of a generic version.

Kmart said Tuesday that in response to the sharp hikes in price of epinephrine auto-injector pens, it has lowered the cost of the generic version of Adrenaclick to as low as $0 for commercially insured patients and $199.99 for cash-paying patients per two-pack.

The reduced price of Adrenaclick is made possible via Kmart’s lowered pricing, combined with a manufacturer’s coupon, the Sears Holdings Corp. discount chain said.

People with anaphylaxis, a potentially life-threatening allergic reaction, will now have more affordable access to an epinephrine auto-injector, compared with the cost of $642.69 a pack for Myland’s EpiPen and $330 for the Mylan generic version of EpiPen.

“When the cost of epinephrine skyrocketed, Kmart understood the critical impact it would have on our customers and worked to make access affordable,” Jennifer Speares Lehman, director of compliance and administration for Kmart Pharmacy, said in a statement. “As part of our ‘Care Beyond the Counter’ approach, Kmart Pharmacy more deeply connects with our customers on issues that matter to them most. Affordable epinephrine auto-injectors is definitely one of them.”

Adrenaclick, from Amedra Pharmaceuticals, an emergency injection of epinephrine used for the treatment of anaphylaxis. With numbered and color-coded instructions, Adrenaclick is designed for single-dose use by patients and caregivers in an anaphylactic emergency.

Kmart noted that according to a 2013 survey of more than 2,000 adults conducted by the Asthma and Allergy Foundation of America, called “Anaphylaxis in America,” people aren’t well-prepared to deal with anaphylaxis, even when they previously have had severe allergic reactions. The survey, published in the Journal of Allergy and Clinical Immunology, found that while most people who experienced anaphylaxis reported two or more reactions during their lifetime, 60% didn’t have an epinephrine self-injection available, and more than half had never been given a prescription for it.



Comments are closed.